Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

5 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.

Direct-acting antiviral therapy prolongs survival in HCV-infected HCC patients

21 Oct 2019

Use of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.

The retrospective study included 797 patients with HCV-related HCC, among whom 383 (48.1 percent) received DAA therapy. All patients achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy.

There were 43 deaths that occurred during 941 person-years of follow-up in the DAA group in comparison with 103 deaths during 526.6 person-years of follow-up in the nontreated group (crude rate ratio, 0.23, 95 percent CI, 0.16–0.33).

Inverse probability-weighted analyses revealed DAA therapy to be associated with a significant decrease in the risk of death (hazard ratio [HR], 0.54, 95 percent CI, 0.33–0.90). This protective association differed by sustained virologic response (SVR) to DAA therapy, such that mortality risk was reduced in patients who achieved SVR (HR, 0.29, 0.18–0.47) but not in those without SVR (HR, 1.13, 0.55–2.33).

Median time from HCC complete response to DAA initiation was 7.7 months, with 20.2 percent of participants treated within 3 months, 21.5 percent between 3 and 6 months, 25.5 percent between 6 and 12 months, and 32.9 percent >12 months after HCC complete response. A total of 79.4 percent of DAA-treated patients achieved SVR, while 11.5 percent had treatment-failure and 9.1 percent had no documented assessment of SVR.

The present data suggest that HCV-infected patients with a history of HCC may benefit from DAA therapies, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

5 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.